Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk.
about
Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell deathSilence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth.Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling.Novel therapeutic approaches for multiple myeloma.Survival and proliferation factors of normal and malignant plasma cells.Pathogenesis beyond the cancer clone(s) in multiple myeloma.Treatment advances in multiple myeloma.Wnts induce migration and invasion of myeloma plasma cellsAnti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts.Targeting signalling pathways for the treatment of multiple myeloma.Growth factors and antiapoptotic signaling pathways in multiple myeloma.Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.The role of microenvironment in tumor angiogenesis.BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasoneMyeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma.Preclinical studies of novel targeted therapies.Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myelomaBortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.Type I insulin-like growth factor receptor signaling in hematological malignancies.Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity.From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.A subset of bone marrow stromal cells regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell lineUrsolic acid-induced apoptosis in K562 cells involving upregulation of PTEN gene expression and inactivation of the PI3K/Akt pathway.Young Adult and Usual Adult Body Mass Index and Multiple Myeloma Risk: A Pooled Analysis in the International Multiple Myeloma Consortium (IMMC).Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo.Microenvironment factors do not afford myeloma cell lines protection from simvastatin.Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma.Insulin-like growth factor-I receptor blockade improves outcome in mouse model of lung injury.The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
P2860
Q31028788-331F3759-9315-4230-9FD2-3C94E6070FE7Q33710200-7A52FF19-9683-48EA-B558-343ED36D3361Q34566043-4F09F00C-3227-4D8B-B113-1CAEFB9C84E0Q35170930-02659267-C3C1-4755-8876-00952B4B5013Q35170935-5C7DE5A8-AF14-42E8-8728-A7D92D29E1DDQ35211028-8D7352BD-8E00-42A1-95FB-98FFE5ABD4F3Q35607266-1C2FD41B-B91D-4157-B78A-52E1815F8547Q35688848-6FAF5D3D-7F8E-4884-9866-2759F7B11320Q35848124-FA785DF2-2017-496E-9914-0F5E071F97FAQ36059640-2FF39795-8B2D-4766-AE42-A22218BB9E83Q36150866-1771FF8F-8941-439A-9255-B5DCA6656357Q36292888-790E4DF5-8672-4119-A5FD-0E3709502C2CQ36367811-CCCD085E-2153-4AD1-B507-6BFB37223B8AQ36474567-710A92BC-4DE8-4158-8CD8-11550F117206Q36558575-7113DB48-8C72-4E3A-93F0-2BADB5531E54Q36663554-81B453D9-AAA2-494A-90C7-CB6DB785502EQ36732811-C1723662-E74B-45F3-A5BE-B0BBB1EB7108Q36742501-A018FE68-2D2D-4579-B045-621304509499Q36932713-927693D1-ED93-4498-B9BB-E219235B9995Q36998210-E6E898AE-28AC-4694-86A7-DD4D69C13CB8Q37140897-6B454EE0-E107-4B84-921D-5D6E7F47BDBAQ37176560-31BABDB2-218B-4229-93DC-E70D48C3E417Q37398728-A01BED4C-F0C1-492B-B215-13D55FA010CEQ37702186-8E17A67F-8756-4E51-8AD0-90B42E1C04EFQ37824564-09A63D09-8CD7-49D8-B0D7-0D2F69F77C6AQ37880074-1F86BE01-83CF-4B4F-AA25-2C3E12D41FFAQ38518964-BD9FE0B5-553C-4C40-9619-7F34853BDB76Q38735514-87946076-9B91-4C68-AF14-243FA5091B05Q38751536-125E6914-7F8B-42EB-A3A6-235B16D78CB6Q38797390-0C48D74C-A68D-4E1A-98D2-E9A0AA37D62FQ38968522-19D7DEED-63A0-4515-9681-EC2FED1F50EAQ39369125-E75B1469-8BCB-40BF-9F4B-A9CFDEFB196FQ40323003-20C05A1F-AB4A-49ED-9260-57C19078593DQ40455737-4985A1BD-161E-4662-A687-83DF4D70E3FAQ40529674-93054FFF-A67D-439D-8DF6-3B59AFEA4F6EQ40706695-E7DF1EBF-AD97-4690-A76A-85EB7F7CA705Q41770950-1DB65EEE-9470-4409-94A8-BC93273F1B7AQ42197476-B23DA500-1BA0-4F10-8970-EFEDBC5CE07AQ43191303-CBE9BDCC-9BC7-4B5C-816A-EF9E61E6DEEDQ44541080-9E337533-940C-4A79-A761-6CD3D9B79D47
P2860
Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Insulinlike growth factor-I si ...... lates, and pathway cross-talk.
@en
Insulinlike growth factor-I si ...... lates, and pathway cross-talk.
@nl
type
label
Insulinlike growth factor-I si ...... lates, and pathway cross-talk.
@en
Insulinlike growth factor-I si ...... lates, and pathway cross-talk.
@nl
prefLabel
Insulinlike growth factor-I si ...... lates, and pathway cross-talk.
@en
Insulinlike growth factor-I si ...... lates, and pathway cross-talk.
@nl
P2093
P1433
P1476
Insulinlike growth factor-I si ...... lates, and pathway cross-talk.
@en
P2093
Eugene Kopantzev
Stuart Rudikoff
Ya-Wei Qiang
P304
P356
10.1182/BLOOD.V99.11.4138
P407
P577
2002-06-01T00:00:00Z